Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||BI 836880 + Ezabenlimab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|BI 836880||BI836880|BI-836880|Bi-specific Anti-VEGF/Ang2 Nanobody BI 836880||VEGF Antibody 10||BI 836880 is a nanobody that binds to both VEGF and ANGPT2, which inhibits downstream signaling, potentially resulting in reduced tumor cell proliferation and inhibition of angiogenesis (NCI Drug Dictionary).|
|Ezabenlimab||BI754091|BI-754091|BI 754091||Immune Checkpoint Inhibitor 153 PD-L1/PD-1 antibody 100||Ezabenlimab (BI 754091) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (J Clin Oncol. 36, no. 5_suppl (February 2018) 212-212).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03468426||Phase I||BI 836880 + Ezabenlimab||A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours||Active, not recruiting||USA | FRA | ESP | DEU||8|